Quantcast

Latest Sirolimus Stories

2009-06-01 09:00:00

 REGiMMUNE Corporation today announced that its lead product candidate RGI-2001, in combination with a low-dose of Sirolimus, demonstrated enhanced efficacy in transplantation tolerance induction in models of skin transplantation and acute Graft-versus-Host disease (GvHD). This data is being presented today in a poster titled "Donor-Specific Tolerance Induction by a Liposomal Formulation of KRN7000 (RGI-2001) Alone and in Combination with Low-Dose Sirolimus" at the 2009 American...

2009-06-01 07:16:28

Fox Chase Cancer Center investigators report that a two-drug blockade of mTOR signaling appears safe in metastatic kidney cancer in a phase I trial. Early data suggests that a combination of temsirolimus and bryostatin may be active in patients with rare forms of renal cell cancer, which are less likely to respond to other targeted therapies.Elizabeth Plimack, M.D., M.S., a medical oncologist and attending physician at Fox Chase will report the trial results on Sunday, May 31 at the annual...

2009-05-29 15:30:00

KRX-0401 Demonstrates Impressive Single Agent Efficacy in Patients who Progressed after Failing Treatment Either with a VEGF Receptor Inhibitor or after Treatment with both a VEGF Receptor Inhibitor and an mTOR Inhibitor NEW YORK, May 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced data on the clinical activity of KRX-0401 (perifosine), the Company's Akt-inhibitor for cancer, as a treatment for advanced renal cell carcinoma. Abstract #5034,...

2009-05-20 12:41:00

Other Presentations Highlight Pre-clinical Work of Company's Future Pro-healing Technologies BARCELONA, Spain, May 20 /PRNewswire/ -- OrbusNeich announced today that two year follow up data from a single center, randomized clinical study in patients at high risk of restenosis were presented at EuroPCR 2009, demonstrating stable results in patients treated with the company's Genous Bio-engineered R stent, the world's first pro-healing stent, compared with results from patients treated with a...

2009-05-14 14:37:14

Osteoporosis, or bone loss, is a disease that is most common in the elderly population, affecting women more often than men. Until now, it was not clear exactly how the disease develops. Researchers of the Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch, Germany, have now elucidated a molecular mechanism which regulates the equilibrium between bone formation and bone resorption. Dr. Jeske J. Smink, Dr. Val©rie B©gay, and Professor Achim Leutz were able to show that two...

2009-05-12 08:30:00

NEW BRUNSWICK, N.J., May 12 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for financial analysts at noon (Eastern Time) on Tuesday, May 19, 2009 to review the primary data from NEVO RES I, the pivotal European trial of the NEVO(TM) Sirolimus-eluting Coronary Stent. NEVO(TM) is the first and only drug-eluting stent utilizing a unique reservoir (RES) technology. Results from this trial will support a design dossier submission for CE Mark approval in...

2009-04-21 19:50:22

Researchers at the University of Chicago Medical Center found that combining 8 ounces of grapefruit juice with the drug rapamycin can increase drug levels. Grapefruit juice can increase blood levels of certain drugs three to five times, Dr. Ezra Cohen, director of the study, said in a statement. This has always been considered a hazard. We wanted to see if, and how much, it could amplify the availability, and perhaps the efficacy of rapamycin, a drug with promise for cancer treatment....

2009-04-21 07:29:00

Data Selected for Presentation Highlights Anti-Tumor effects of KRX-0401 (Perifosine) NEW YORK, April 21 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced multiple presentations of preclinical data highlighting the anti-tumor effects of KRX-0401 (perifosine), the company's lead anti-cancer compound, at the American Association of Cancer Research (AACR) Annual Meeting, being held in Denver, Colorado. Abstracts selected for presentation today, Tuesday,...

15c3792dd8efea62510f42f9486889e31
2009-04-21 08:14:35

In a small, early clinical trial, researchers at the University of Chicago Medical Center have found that combining eight ounces of grapefruit juice with the drug rapamycin can increase drug levels, allowing lower doses of the drug to be given. They also showed that the combination can be effective in treating various types of cancer. For two decades, pharmacists have pasted DO-NOT-TAKE-WITH-GRAPEFRUIT-JUICE stickers on various pill bottles because it can interfere with the enzymes that break...

2009-03-30 15:01:00

- Afinitor more than doubled time without tumor growth and reduced the risk of disease progression or death by 67% compared with placebo - Only once-daily oral cancer treatment to directly target mTOR, a protein inside the cell that controls tumor cell division and blood vessel growth - Phase III trials underway to explore potential of Afinitor in multiple additional cancers EAST HANOVER, N.J., March 30 /PRNewswire/ -- Novartis announced today that Afinitor(R) (everolimus) tablets has been...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related